Published

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Headache
Date: 2026-04-01
Source: PubMed
DOI: 10.1111/head.70024
PubMed: 41459830

Authors

Schindler EAD Gottschalk CH Pittman BP D'Souza DC

Watch author

Derived topics and classifications

psilocybin Headache / Migraine Clinical Trial Randomized Controlled Trial Safety Adverse Events Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.2026-04-01

Related papers

Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?Ask the expert - Psychedelic substances · 2024-08-31 Med Check: Psilocybin for OCD, Nuplazid Vote, and MorePsychiatric News · 2022-08-01 A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol DependenceClinicalTrials.gov · 2022-11-08 Psilocybin-facilitated Treatment for Cocaine UseClinicalTrials.gov · 2026-05-18